Search

Your search keyword '"Seidman, Andrew"' showing total 641 results
Start Over Author "Seidman, Andrew"
641 results on '"Seidman, Andrew"'

201. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B

Author

Polite, Blase N., primary, Cirrincione, Constance, additional, Fleming, Gini F., additional, Berry, Donald A., additional, Seidman, Andrew, additional, Muss, Hyman, additional, Norton, Larry, additional, Shapiro, Charles, additional, Bakri, Kamal, additional, Marcom, Kelly, additional, Lake, Diana, additional, Schwartz, Joel H., additional, Hudis, Clifford, additional, and Winer, Eric P., additional

Published
2008
Full Text
View/download PDF

202. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Author

Seidman, Andrew D., primary, Berry, Donald, additional, Cirrincione, Constance, additional, Harris, Lyndsay, additional, Muss, Hyman, additional, Marcom, P. Kelly, additional, Gipson, Grandella, additional, Burstein, Harold, additional, Lake, Diana, additional, Shapiro, Charles L., additional, Ungaro, Peter, additional, Norton, Larry, additional, Winer, Eric, additional, and Hudis, Clifford, additional

Published
2008
Full Text
View/download PDF

204. The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer

Author

Dang, Chau, primary, Fornier, Monica, additional, Sugarman, Steven, additional, Troso-Sandoval, Tiffany, additional, Lake, Diana, additional, D'Andrea, Gabriella, additional, Seidman, Andrew, additional, Sklarin, Nancy, additional, Dickler, Maura, additional, Currie, Violante, additional, Gilewski, Theresa, additional, Moynahan, Mary Ellen, additional, Drullinsky, Pamela, additional, Robson, Mark, additional, Wasserheit-Leiblich, Carolyn, additional, Mills, Nancy, additional, Steingart, Richard, additional, Panageas, Katherine, additional, Norton, Larry, additional, and Hudis, Clifford, additional

Published
2008
Full Text
View/download PDF

205. Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients

Author

Deng, Gary, primary, Vickers, Andrew J., additional, Yeung, K. Simon, additional, D'Andrea, Gabriella M., additional, Xiao, Han, additional, Heerdt, Alexandra S., additional, Sugarman, Steven, additional, Troso-Sandoval, Tiffany, additional, Seidman, Andrew D., additional, Hudis, Clifford A., additional, and Cassileth, Barrie R., additional

Published
2007
Full Text
View/download PDF

209. Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer

Author

Fornier, Monica N., primary, Seidman, Andrew D., additional, Lake, Diana, additional, D'Andrea, Gabriella, additional, Bromberg, Jacqueline, additional, Robson, Mark, additional, Van Poznak, Catherine, additional, Panageas, Katherine S., additional, Atienza, Marietta, additional, Norton, Larry, additional, and Hudis, Clifford, additional

Published
2007
Full Text
View/download PDF

211. Egf Receptor Mabs and Chemotherapy/Characterization of Synergistic Interactions Between Cyrotoxic Agents and Inhibitors of the Tyrosine Kinase Growth Factor Receptor Signaling Cascade

Author

SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK, Seidman, Andrew, SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK, and Seidman, Andrew

Abstract

The focus of the laboratory and correlative science projects funded by this grant derive from the observation that antibodies directed against the EGFR receptor (225) and HER2 tyrosine kinase (4D5, trastuzumab) are effective in treating breast cancer in preclinical models. In the case of trastuzumab, these data have been extended to the treatment of human disease. Furthermore, Baselga and Mendelsohn and others have shown that inhibition of these tyrosine kinases with antireceptor antibodies augments the activity of a variety of cytotoxic agents. These results have been validated in large, prospective clinical trials, in which trastuzumab has meaningfully improved survival for patients with HER2/neu overexpressing metastatic breast cancer when combined with paclitaxel or doxorubicin + cyclophosphamide. This report describes that drugs that inhibit other elements in the HER-kinase signaling pathway also inhibit breast cancer cells, and determines whether such inhibitors synergize with taxanes, to better elucidate the function of HER2 in breast cancer. Our investigation of the immunophenotypic characterization of human breast cancers for molecular markers thought to be potential correlates of the antitumor activity of taxanes, examining HER2 among other candidates, is similarly relevant to optimizing and individualizing anti-cancer treatment.

Published
1999

213. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer

Author

Modi, Shanu, primary, DiGiovanna, Michael P., additional, Lu, Zhao, additional, Moskowitz, Chaya, additional, Panageas, Katherine S., additional, Van Poznak, Catherine, additional, Hudis, Clifford A., additional, Norton, Larry, additional, Tan, Lee, additional, Stern, David F., additional, Carter, Darryl, additional, and Seidman, Andrew D., additional

Published
2005
Full Text
View/download PDF

215. Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

Author

Dang, Chau T., primary, D’Andrea, Gabriella M., additional, Moynahan, Mary E., additional, Dickler, Maura N., additional, Seidman, Andrew D., additional, Fornier, Monica, additional, Robson, Mark E., additional, Theodoulou, Maria, additional, Lake, Diana, additional, Currie, Violante E., additional, Hurria, Arti, additional, Panageas, Katherine S., additional, Norton, Larry, additional, and Hudis, Clifford A., additional

Published
2004
Full Text
View/download PDF

216. Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Author

Dang, Chau T., primary, Dannenberg, Andrew J., additional, Subbaramaiah, Kotha, additional, Dickler, Maura N., additional, Moasser, Mark M., additional, Seidman, Andrew D., additional, D’Andrea, Gabriella M., additional, Theodoulou, Maria, additional, Panageas, Katherine S., additional, Norton, Larry, additional, and Hudis, Clifford A., additional

Published
2004
Full Text
View/download PDF

218. EgF Receptor Mabs and Chemotherapy/Characterization of Synergistic Interactions Between Cytotoxic Agents and Inhibitors of the Tyrosine Kinase Growth Factor Receptor Signalling Cascade

Author

MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, Seidman, Andrew D., MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, and Seidman, Andrew D.

Abstract

Human epidermal growth factor receptor (EGFR, HER1) and HER2 are transmembrane receptors possessing intrinsic tyrosine kinase activity. Preclinical and more recently, clinical demonstration of synergism between antibodies directed at these receptors and chemotherapeutic agents has focused our present efforts on the characterization of synergistic interactions between cytotoxic drugs and inhibitors of the tyrosine kinase growth factor signalling cascade. While we have encountered obstacles, both clinical toxicity as well as operational difficulties, in the investigation of the chimeric monoclonal antibody C225 (directed at EGFR) + paclitaxel, as summarized within this report, we have subsequently proceeded rapidly and successfully with clinical evaluation of weekly trastuzumab (HER2-directed) + weekly paclitaxel. The present report describes our most recent efforts to molecularly characterize this synergy, to perform preclinical evaluation of antitubulin agents (taxanes, vincas, and epothilones) alone and in combination with famesyl protein transferase inhibitors in mammary carcinoma cells, and to better define molecular predictors of response to inhibitors of mitogenic signal transduction, taxanes, and combinations of these agents.

Published
1998

229. Cardiac Dysfunction in Clinical Trials of Trastuzumab

Author

Page, Eric, primary, Assouline, David, additional, Brun, Odile, additional, Coeffic, David, additional, Fric, Danièle, additional, Winckel, Philippe, additional, Seidman, Andrew D., additional, Pierri, Mary Kathryn, additional, and Hudis, Clifford, additional

Published
2002
Full Text
View/download PDF

232. EGF Receptor Mabs and Chemotherapy in Breast Cancer.

Author

MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, Norton, Larry, Seidman, Andrew, MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, Norton, Larry, and Seidman, Andrew

Abstract

To establish a safety profile in patients with Stage IV, EGFr positive breast cancer, for which no curative standard exists, of C225 over a range of dose levels and to pharmacologically optimize the dosing regimen of loading and maintenance infusions administered during combination chemotherapy with weekly doses of paclitaxel.

Published
1996

233. Development of Inhibitors of HER2 With Taxanes.

Author

Teicher, Beverly A., Schwartz, Gary K., Modi, Shanu, Fornier, Monica N., and Seidman, Andrew D.

Abstract

The development of superior treatment strategies directed against metastatic breast cancer remains a major challenge. Because this condition is historically treatable but not curable, the primary goal of clinical management is often to create an optimal equilibrium between maximizing response, minimizing toxicity, improving survival, and optimizing symptom palliation. The search for new drugs that might provide these characteristics, together with an expanding understanding of the molecular basis of cancer, has prompted the development and investigation of "biologic" agents, which offer high tumor selectivity together with a favorable therapeutic ratio. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

235. Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

Author

Van Poznak, Catherine, primary, Seidman, Andrew D., additional, Reidenberg, Marcus M., additional, Moasser, Mark M., additional, Sklarin, Nancy, additional, Van Zee, Kimberly, additional, Borgen, Patrick, additional, Gollub, Marc, additional, Bacotti, Doreen, additional, Yao, T-J, additional, Bloch, Renny, additional, Ligueros, Monica, additional, Sonenberg, Martin, additional, Norton, Larry, additional, and Hudis, Clifford, additional

Published
2001
Full Text
View/download PDF

238. Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions.

Author

Morikawa, Aki, Jhaveri, Komal, and Seidman, Andrew D.

Abstract

Brain metastases (BM) portend a poor prognosis among breast cancer patients. The management of breast cancer with brain metastases (BCBM) is multi-modal with local therapy consisting of radiation and/or surgery, albeit without durable responses, and systemic therapy playing an increasingly important role. Further clinical research is warranted to improve prognosis for BCBM. However, there are several challenges in studying this population. This review provides a general overview of BCBM and discusses unique aspects of conducting clinical trials and ongoing/future research in BCBM. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

239. Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel

Author

Hudis, Clifford, primary, Riccio, Louise, additional, Seidman, Andrew, additional, Baselga, Jose, additional, Currie, Violante, additional, Fennelly, David, additional, Gilewski, Teresa, additional, Lebwohl, David, additional, Moynahan, Maryellen, additional, Raptis, George, additional, Surbone, Antonella, additional, Sklarin, Nancy, additional, Yao, T. J., additional, Keefe, Deborah, additional, and Norton, Larry, additional

Published
1998
Full Text
View/download PDF

244. Taxol (Paclitaxel) plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Metastatic Breast Cancer

Author

Seidman, Andrew D., primary, Norton, Larry, additional, Reichman, Bonnie S., additional, Crown, John P.A., additional, Yao, T.J., additional, Hakes, Thomas B., additional, Lebwohl, David E., additional, Gilewski, Theresa A., additional, Hudis, Clifford A., additional, Surbone, Antonella, additional, Currie, Violante, additional, Klecker, Raymond, additional, Jamis-Dow, Carlos, additional, Collins, Jerry, additional, Marks, Linda, additional, Quinlivan, Susan, additional, Berkery, Regina, additional, Canetta, Renzo, additional, Onetto, Nicole, additional, and Arbuck, Susan, additional

Published
1994
Full Text
View/download PDF

246. Hepatic Arterial Infusion and Systemic Chemotherapy for Breast Cancer Liver Metastases.

Author

Ang, Celina, Jhaveri, Komal, Patel, Dina, Gewirtz, Alexandra, Seidman, Andrew, and Kemeny, Nancy

Subjects
ANTINEOPLASTIC agents, BREAST tumors, CANCER chemotherapy, LIVER tumors, METASTASIS, SURVIVAL, DESCRIPTIVE statistics, DISEASE complications
Abstract

Hepatic failure from breast cancer liver metastases ( BCLM) is a major cause of morbidity and mortality. We reviewed the treatment histories and outcomes of nine patients with heavily treated BCLM, who received hepatic arterial infusion ( HAI) of floxuridine ( FUDR)/dexamethasone (Dex) and systemic chemotherapy at our institution. Patients received a median of five (range 1-15) HAI treatments. There were seven (78%) objective responses. Four patients had grade 3 elevations in liver enzymes attributable to HAI. There were no treatment-related deaths. Median hepatic and extrahepatic time to progression on HAI were both 6 months. Median survival after starting HAI was 17 months (range 1-115). Median overall survival from the original breast cancer diagnosis was 110 months (range 52-248). One patient is alive with stable disease on systemic therapy alone. HAI and systemic chemotherapy is feasible and can benefit selected patients with BCLM, who have progressed on prior therapies. Patients require close monitoring for treatment-limiting toxicities. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

247. Taxol and Recombinant Human Granulocyte Colony-Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer.

Author

REICHMAN, BONNIE S., primary, SEIDMAN, ANDREW D., additional, CROWN, JOHN P. A., additional, HEELAN, ROBERT, additional, YAO, T. J., additional, HAKES, THOMAS B., additional, LEBWOHL, DAVID E., additional, GILEWSKI, THERESA A., additional, SURBONE, ANTONELLA, additional, CURRIE, VIOLANTE, additional, HUDIS, CLIFFORD A., additional, QUINLIVAN, SUSAN, additional, BERKERY, REGINA, additional, TOOMASI, FRIEDA, additional, CANETTA, RENZO, additional, FISHERMAN, JASON, additional, ARBUCK, SUSAN, additional, and NORTON, LARRY, additional

Published
1993
Full Text
View/download PDF

249. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping.

Author

Schwartz, Gordon F., Bartelink, Harry, Burstein, Harold J., Cady, Blake, Cataliotti, Luigi, Fentiman, Ian S., Holland, Roland, Hughes, Kevin S., Masood, Shahla, McCormick, Beryl, Palazzo, Juan A., Pressman, Peter I., Reis-Filho, Jorge, Pusztai, Lajos, Rutgers, Emiel J. T., Seidman, Andrew D., Solin, Lawrence J., and Sparano, Joseph A.

Subjects
BREAST tumors, COMBINED modality therapy, GENES, TUMOR classification
Abstract

A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

250. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer.

Author

Morris, Patrick G., Murphy, Conleth G., Mallam, Divya, Accordino, Melissa, Patil, Sujata, Howard, Jane, Omuro, Antonio, Beal, Kathryn, Seidman, Andrew D., Hudis, Clifford A., and Fornier, Monica N.

Subjects
METASTASIS, BRAIN tumors, BREAST tumors, CONFIDENCE intervals, SURVIVAL, RETROSPECTIVE studies, DESCRIPTIVE statistics, PROGNOSIS
Abstract

Patients with breast cancer, which lacks ER, PR, and HER2; 'triple negative' (TNBC), are at increased risk of brain metastases (BMs). However, the impact of modern therapy on the risk of BMs and outcomes remains largely unknown. In this retrospective, single-institution study we assessed the incidence of BMs, the therapeutic options, and overall survival, in a recent cohort of patients with TNBC. Women diagnosed with early stage TNBC from January 1, 1998 to December 31, 2007 were identified through institutional databases. Electronic medical records were reviewed to assess patterns of recurrence, treatment, and survival. In total, 1,323 patients, median age 53 years (range 20-91), were identified. There were 298 patients (23%) who developed metastatic disease, of whom, 99 (33%) developed BMs, representing 7.5% of the entire cohort. Following BM diagnosis, treatment consisted of: radiotherapy 87 (88%) patients, resection 26 (26%) patients, and systemic chemotherapy 70 (71%) patients, with a median of 1.0 (range 0-8) chemotherapy regimens. The actuarial median survival from diagnosis of BMs is 5 months (95% CI 4-7 months). This single-institution, retrospective study confirms that the prognosis for patients with BMs from TNBC remains poor. This group of patients urgently needs improved therapies. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results